JP2017535525A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535525A5
JP2017535525A5 JP2017517316A JP2017517316A JP2017535525A5 JP 2017535525 A5 JP2017535525 A5 JP 2017535525A5 JP 2017517316 A JP2017517316 A JP 2017517316A JP 2017517316 A JP2017517316 A JP 2017517316A JP 2017535525 A5 JP2017535525 A5 JP 2017535525A5
Authority
JP
Japan
Prior art keywords
methoxy
phenyl
amino
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517316A
Other languages
English (en)
Japanese (ja)
Other versions
JP6608918B2 (ja
JP2017535525A (ja
Filing date
Publication date
Priority claimed from GBGB1417344.7A external-priority patent/GB201417344D0/en
Priority claimed from GBGB1510694.1A external-priority patent/GB201510694D0/en
Application filed filed Critical
Priority claimed from PCT/GB2015/052876 external-priority patent/WO2016051187A1/en
Publication of JP2017535525A publication Critical patent/JP2017535525A/ja
Publication of JP2017535525A5 publication Critical patent/JP2017535525A5/ja
Application granted granted Critical
Publication of JP6608918B2 publication Critical patent/JP6608918B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517316A 2014-10-01 2015-10-01 P38キナーゼ阻害剤としてのジアリール尿素誘導体 Expired - Fee Related JP6608918B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1417344.7 2014-10-01
GBGB1417344.7A GB201417344D0 (en) 2014-10-01 2014-10-01 New compounds
GBGB1510694.1A GB201510694D0 (en) 2015-06-18 2015-06-18 New compounds
GB1510694.1 2015-06-18
PCT/GB2015/052876 WO2016051187A1 (en) 2014-10-01 2015-10-01 Diaryl urea derivatives as p38 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017535525A JP2017535525A (ja) 2017-11-30
JP2017535525A5 true JP2017535525A5 (https=) 2018-11-08
JP6608918B2 JP6608918B2 (ja) 2019-11-20

Family

ID=54337298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017517316A Expired - Fee Related JP6608918B2 (ja) 2014-10-01 2015-10-01 P38キナーゼ阻害剤としてのジアリール尿素誘導体
JP2017517315A Expired - Fee Related JP6662863B2 (ja) 2014-10-01 2015-10-01 P38キナーゼ阻害剤としての4−(4−(4−フェニルウレイドナフタレン−1−イル)オキシピリジン−2−イル)アミノ安息香酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017517315A Expired - Fee Related JP6662863B2 (ja) 2014-10-01 2015-10-01 P38キナーゼ阻害剤としての4−(4−(4−フェニルウレイドナフタレン−1−イル)オキシピリジン−2−イル)アミノ安息香酸誘導体

Country Status (12)

Country Link
US (6) US9751837B2 (https=)
EP (2) EP3201180A1 (https=)
JP (2) JP6608918B2 (https=)
KR (2) KR20170063783A (https=)
CN (2) CN106999478A (https=)
AU (2) AU2015326543B2 (https=)
BR (2) BR112017005531A2 (https=)
CA (1) CA2961870A1 (https=)
EA (2) EA032694B1 (https=)
MA (2) MA40774A (https=)
MX (2) MX373658B (https=)
WO (2) WO2016051188A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
CN103917536B (zh) 2011-10-03 2016-07-06 瑞斯比维特有限公司 1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
KR102283876B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제로서 유용한 우레아 유도체
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
EP3083604A1 (en) * 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
ES2677595T3 (es) 2014-02-14 2018-08-03 Respivert Limited Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
MA40774A (fr) * 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CA3015978A1 (en) * 2016-04-06 2017-10-12 Topivert Pharma Limited Kinase inhibitors
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) * 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2022010764A1 (en) * 2020-07-06 2022-01-13 Vivtex Corporation Mucopenetrating formulations
EP4288041A1 (en) * 2021-02-08 2023-12-13 Bausch Health Ireland Limited Amiselimod for preventing, treating, or ameliorating ulcerative colitis
WO2022204046A1 (en) * 2021-03-23 2022-09-29 Gen1E Lifesciences Inc. Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
EP4705280A1 (en) * 2023-05-02 2026-03-11 Purdue Research Foundation Diaryl urea-based compounds and related compositions and methods of use in the treatment of diabetes mellitus and neurodegenerative disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023091A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
MXPA03009000A (es) 2001-04-13 2004-02-12 Boehringer Ingelheim Pharma Compuestos benzo-fusionados 1,4-disustituidos.
MXPA03009361A (es) 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
WO2002092576A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
ATE386030T1 (de) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
TW200406374A (en) * 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CA2494824A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
WO2004113352A1 (en) 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silylated heterocyclylurea derivatives as cytokine-inhibitors
EP1644341A1 (en) 2003-06-30 2006-04-12 Boehringer Ingelheim Pharmaceuticals Inc. Process of making di-aryl urea compounds
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005044825A1 (en) 2003-10-21 2005-05-19 Amedis Pharmaceuticals Ltd. Silicon compounds and their use
GB0327734D0 (en) * 2003-11-28 2003-12-31 Novartis Ag Organic compounds
JP2007515400A (ja) 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DOP2006000234A (es) 2005-10-28 2007-05-31 Lilly Co Eli Inhibidores de cinasa
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP5670912B2 (ja) 2008-12-11 2015-02-18 レスピバート・リミテツド p38MAPキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102482233A (zh) * 2009-05-21 2012-05-30 阿斯利康(瑞典)有限公司 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124923A2 (en) 2010-04-08 2011-10-13 Respivert Limited Novel compounds
EP2556068B1 (en) 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
RU2571357C2 (ru) 2010-05-11 2015-12-20 Бревилл Пти Лимитед Способ работы кофеварки эспрессо и устройство для его осуществления
GB201010196D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
CN103917536B (zh) 2011-10-03 2016-07-06 瑞斯比维特有限公司 1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
KR102283876B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제로서 유용한 우레아 유도체
EP3083604A1 (en) * 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3102283B1 (en) * 2014-02-05 2018-02-28 Boston Scientific Neuromodulation Corporation System for delivering modulated sub-threshold therapy to a patient
ES2677595T3 (es) 2014-02-14 2018-08-03 Respivert Limited Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3201189A1 (en) 2014-10-01 2017-08-09 Respivert Limited N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2017535525A5 (https=)
JP2017502033A5 (https=)
JP6505013B2 (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2016515606A5 (https=)
JP6608918B2 (ja) P38キナーゼ阻害剤としてのジアリール尿素誘導体
JP2016519680A5 (https=)
ES2371265T3 (es) Amidas de ácido 3-heterociclil-3-hidroxi-2-amino-propiónico y compuestos relacionados que tienen actividad analgésica y/o inmunoestimulante.
JP2017511794A5 (https=)
JP2017533895A5 (https=)
JP2021534124A5 (https=)
RU2016110412A (ru) Некоторые химические соединения, композиции и способы
JP2016530274A5 (https=)
JP2012501313A5 (https=)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
JP2014520809A5 (https=)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2017525757A5 (https=)
JP2008517945A5 (https=)
RU2009119290A (ru) Производные гидантоина, используемые в качестве ингибиторов ммр
JP2016515606A (ja) キナーゼ阻害剤として有用な尿素誘導体
JP2016503009A5 (https=)
US20170114083A1 (en) Compounds and compositions as kinase inhibitors
HRP20151317T1 (hr) Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
CN107635975B (zh) Dgat2抑制剂